All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

It’s the Intensity, Not the Hours, That Makes Fellowship Challenging

March 12th 2023

Kevin Raskin, MD, discusses time management, the importance of taking time off, and teaching fellows how to listen to their inner voice.

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

March 11th 2023

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

March 10th 2023

Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.

A Primer on Job Hunting

March 10th 2023

Although the formal process of investigating a job takes time and effort, the reality is that you started interviewing for your first job on the first day of your fellowship.

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

$8 million gift establishes research fund, endowed position for bile duct cancer at IU

March 10th 2023

IU School of Medicine alumnus Kip E. Virts, MD, has made an $8 million estate gift to support bile duct cancer research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

China’s NMPA Accepts BLA for Enfortumab Vedotin in Locally Advanced/Metastatic Urothelial Cancer

March 10th 2023

The Center for Drug Evaluation of the China National Medical Products Administration has accepted the biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.

Pembrolizumab Plus Chemotherapy Meets OS End Point in Advanced Malignant Pleural Mesothelioma

March 10th 2023

First-line treatment with the combination of pembrolizumab and chemotherapy generated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Will Immunotherapy Become a Standard of Care for Glioblastoma?

March 10th 2023

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

The combination of cabozantinib and atezolizumab elicited responses in patients with non–clear cell renal cell carcinoma, according to extended follow-up data from the phase 1b COSMIC-021 trial.

FDA Panel Votes in Support of Favorable Benefit-Risk Profile for Polatuzumab Vedotin in Previously Untreated LBCL

March 9th 2023

The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 that data from the phase 3 POLARIX trial support a favorable benefit-risk profile for polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.

Minimally Invasive Surgery, PARP Inhibitors, ADCs Propel Treatment Advances Across Gynecologic Oncology

March 9th 2023

Jubilee Brown, MD, discusses future considerations for using minimally invasive surgery and PARP inhibitors in ovarian cancer, how immunotherapies have fulfilled an unmet need in cervical cancer, and the importance of leveraging molecular profiling to determine personalized therapeutic strategies in endometrial cancer.

Durvalumab-Based Treatment Before and After Surgery Improves EFS in Early-Stage NSCLC

March 9th 2023

Durvalumab plus neoadjuvant chemotherapy followed by surgery and adjuvant single-agent durvalumab significantly improved event-free survival vs neoadjuvant chemotherapy and surgery alone in patients with resectable stage IIA-IIIB non–small cell lung cancer.

COVID-19 Vaccine Efficacy Decreases With Ruxolitinib Use in MPNs

March 9th 2023

Treatment with ruxolitinib impaired antibody responses to complete vaccination with the BNT162b2 SARS-CoV-2 vaccine in patients with myelofibrosis or polycythemia vera.

Study Shows Women Over Age 65 With Low-risk Breast Cancer Could Skip Postoperative Radiation Therapy

March 9th 2023

A recently published study in the New England Journal of Medicine provides further data to support that certain female patients over age 65 can achieve positive outcomes without postoperative radiation.

Adjuvant Osimertinib Elicits OS Improvement in Early-Stage EGFR-Mutated NSCLC

March 9th 2023

Osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo as adjuvant treatment for patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer after complete tumor resection with curative intent.

STELLAR-303 Aims to Carve Out Space for XL092 in mCRC Treatment Paradigm

March 9th 2023

Despite incremental advances in the treatment landscape of metastatic colorectal cancer, patients with the disease still face a poor prognosis.

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

March 9th 2023

The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.

FDA Grants Fast Track Designation to IK-175 in Combination With Nivolumab in Urothelial Carcinoma

March 8th 2023

The FDA has granted a fast track designation to the novel aryl hydrocarbon receptor antagonist IK-175 in combination with nivolumab for the treatment of patients with advanced urothelial carcinoma who have progressed on or within 3 months of receiving the last dose of checkpoint inhibitors.

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

March 8th 2023

Susan M. Domchek, MD, highlights key points related to her presentation on germline testing and breast cancer treatment.